FGI-104
FGI-104 is the name of an experimental broad-spectrum antiviral drug, with activity against a range of viruses including Hepatitis B, Hepatitis C, HIV, Ebola virus and Venezuelan equine encephalitis virus. [1]
 | |
| Legal status | |
|---|---|
| Legal status | |
| Identifiers | |
| |
| PubChem CID | |
| Chemical and physical data | |
| Formula | C28H30ClN3O3 |
| Molar mass | 492.008 g·mol−1 |
| 3D model (JSmol) | |
| |
Mechanism
The drug acts by inhibiting the protein TSG101, which transports newly manufactured virions to the exterior of an infected cell, thus breaking the replication cycle of the virus. In pre-clinical studies, FGI-104 has been shown to protect mice from Ebola virus disease.[2]
References
- Kinch MS, Yunus AS, Lear C, Mao H, Chen H, Fesseha Z, et al. (January 2009). "FGI-104: a broad-spectrum small molecule inhibitor of viral infection". American Journal of Translational Research. 1 (1): 87–98. doi:10.1016/j.antiviral.2009.02.082. PMC 2776286. PMID 19966942.
- Janeba Z (November 2015). "Development of Small-Molecule Antivirals for Ebola". Medicinal Research Reviews. 35 (6): 1175–94. doi:10.1002/med.21355. PMC 7168439. PMID 26172225.
| Ebolavirus |
| ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Marburgvirus |
| ||||||||||||
| Cuevavirus |
| ||||||||||||
| Dianlovirus |
| ||||||||||||
| Striavirus |
| ||||||||||||
| Thamnovirus |
| ||||||||||||
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.